Risiko Kanker Akibat Penggunaan Proton Pump Inhibitor Jangka Panjang

Oleh :

dr. Vania Azalia Gunawan

Penggunaan proton pump inhibitor (PPI) jangka panjang telah dikaitkan dengan peningkatan risiko kanker, seperti kanker lambung dan kanker pankreas. Obat golongan PPI, seperti omeprazole dan lansoprazole, merupakan obat penekan asam yang banyak digunakan dalam penanganan berbagai kondisi medis, termasuk gastritis, gastroesophageal reflux disease (GERD), dan ulkus peptikum. Karena gejala kondisi tersebut sering rekuren, PPI menjadi kerap digunakan dalam jangka lama.[1,2]

Risiko Penggunaan PPI Jangka Panjang terhadap Kanker Lambung

Contoh proton pump inhibitor (PPI) adalah omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, dan rabeprazole. Efek PPI sebagai obat penekan asam yang poten dicurigai meningkatkan risiko kanker lambung. Hal ini diduga berkaitan dengan perburukan atrofi lambung, peningkatan kondisi hipergastrinemia, dan peningkatan bacterial overgrowth pada lambung yang timbul akibat penggunaan PPI jangka panjang.[2,3]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Hong HE, Kim AS, Kim MR, Ko HJ, Jung MK. Does the Use of Proton Pump Inhibitors Increase the Risk of Pancreatic Cancer? A Systematic Review and Meta-Analysis of Epidemiologic Studies. Cancers (Basel). 2020;12(8):2220.
2. Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus. 2019;11(9):e5563.
3. Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019; 12: 1756284819834511.
4. Poly TN, Lin MC, Syed-Abdul S, Huang CW, Yang HC, Li YJ. Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal. Cancers (Basel). 2022;14(13):3052.
5. Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022; 71:16-24.
6. Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55(4):453-461.
7. Lasalle M, Tri TL, Afchain P, Camus M, Kirchgesner J, Zureik M, Dray-Spira R. Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case–Control Study Based on the French National Health Data System (SNDS). Cancer Epidemiol Biomarkers Prev. 2022; 31(3):662-669.
8. Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2022;20(2):e196-e227.
9. Choi HG, Lee HK, Kang HS, Lim H, Kim JH, Kim JH, Kim NY, Cho SJ, Nam ES, Min KW, Kwon MJ. Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case-Control Study Using a Korean National Health Screening Cohort. Pharmaceuticals (Basel). 2022;15(5):517.
10. Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018 Apr;53:172-177.
11. Jiang K, Jiang X, Wen Y, Liao L, Liu FB. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol. 2019 Nov;34(11):1898-1905. doi: 10.1111/jgh.14759. Epub 2019 Jul 24. PMID: 31206764.
12. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017 Oct 30;7(10):e017739. doi: 10.1136/bmjopen-2017-017739. PMID: 29084798; PMCID: PMC5665226.